Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. - Wikidata - wikimedia - TriplyDB

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

http://www.wikidata.org/entity/Q36399686

about

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells Adoptive T cell therapy for cancer in the clinic Adoptive T cell therapy: Addressing challenges in cancer immunotherapy Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Translating Treg Therapy in Humanized Mice Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment A central role for inducible heat-shock protein 70 in autoimmune vitiligo Modulation of GITR for cancer immunotherapy The effect of radiation on the immune response to cancers Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Novel immunotherapies for hematologic malignancies Targeting regulatory T cells in cancer Suppression, subversion and escape: the role of regulatory T cells in cancer progression Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview Immunosuppression associated with chronic inflammation in the tumor microenvironment TGF-beta: a mobile purveyor of immune privilege Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma Immunosuppressive networks in the tumour environment and their therapeutic relevance Immunosuppressive strategies that are mediated by tumor cells Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape.IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor grow Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer Administration of cyclophosphamide changes the immune profile of tumor-bearing mice The role of regulatory T cells in cancer.Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts Prolonged survival of allografts induced by mycobacterial Hsp70 is dependent on CD4+CD25+ regulatory T cells.Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

P2860

Q24540135-D19F31D3-93A5-4071-B1EA-3FB9FB65C579 Q24680405-166192AC-3775-4324-B97A-9E242A51D1F9 Q24805804-0AD17236-47BB-4D02-A9B8-A704330C1904 Q26765459-5D38F9DD-E0CB-4771-96CB-BA2BC05962A2 Q26772335-7B5B2531-3D3A-44A6-93A6-3DD2B71EB6C1 Q26799117-D3622267-0BDF-4787-9847-DFBFB783EE91 Q26823593-E038F44B-ECFB-4C5A-9FA0-94633516E7A6 Q26853557-33C69975-68ED-4804-9A53-7A78B45C10A1 Q26995372-B3B0BF68-4663-458D-9797-C2FFF2034628 Q27004178-5E072453-7F46-4309-BA90-D78E4601CCA4 Q27004436-0E2EF29E-E7B1-4496-B352-D0FD749DCE21 Q27022348-B5CBD695-3C0D-43EE-BCE3-4388DEB1182F Q27026151-5099300E-E684-4782-8DFF-35C293108F7D Q27317214-A6A587BE-914A-4672-B402-86165B65575E Q27334728-8C7A9F67-ADFA-4D64-9416-CA327456DB84 Q28075992-58E0A151-BFB3-48C7-BE49-942186C59253 Q28081582-B8A49BFA-6513-4C18-A7FF-8A7D4338F80F Q28083450-AC056D75-A8D1-4109-82F7-A575205BB734 Q28263622-7CF979F9-7FA0-49B2-A1B4-7E847BF10E1A Q28475223-CDCF6D5D-1380-4483-A33A-04073B375DCA Q28731711-379AB5F8-AB6E-4599-9166-584DA770A6B1 Q29619244-3CAF7315-F93F-42A5-82C0-FC687608FC5E Q29636247-BEFC8F41-7174-4DF1-89CB-8331C6D412EA Q30363260-C67E7EF3-DC5A-4FC0-85A6-1C8848D2560B Q30481064-8240D2FC-2A8D-4F22-99A4-39BB05DF1A84 Q33563230-ACBB1361-5AA8-4F60-A1A7-2301312C7B21 Q33573450-5E17AFE5-879C-405B-88AF-DF25735A45BB Q33598811-D4EB1133-3C30-42B8-A86D-68EF835C5A71 Q33608626-77062CB3-2022-4743-B20F-DC604279D7D8 Q33611809-830A90F3-1C90-40C2-880A-2DBC5E6491CC Q33631986-948F4FFF-804B-463A-A845-B6D8CB6EE0EB Q33737660-7EEB190A-00FA-4189-8E41-A949D298AA16 Q33765767-15BAC154-C281-48D2-B483-70E56657811A Q33772479-B2039C2C-D888-48F4-817A-8DECC91B2061 Q33775679-726B51CA-67B3-4F49-90B3-8F5F8C9344CB Q33829513-C3D01A5E-0AB8-4A6E-91E8-56E3DDC49DA5 Q33831940-926D6F08-0A3F-4263-99F2-289D0E03B156 Q33865610-7049D0F4-6215-4079-BC40-A310BE1EF214 Q33896713-739027B1-442E-4201-8114-C8F13516960B Q33933665-56CBBB9D-BBE7-4066-9EED-3F54A11D3BC4

P2860

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

http://www.wikidata.org/entity/Q36399686

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Concomitant tumor immunity to ...... evented by regulatory T cells.

@ast

Concomitant tumor immunity to ...... evented by regulatory T cells.

@en

type

label

Concomitant tumor immunity to ...... evented by regulatory T cells.

@ast

Concomitant tumor immunity to ...... evented by regulatory T cells.

@en

prefLabel

Concomitant tumor immunity to ...... evented by regulatory T cells.

@ast

Concomitant tumor immunity to ...... evented by regulatory T cells.

@en

P1433

Q36399686-BB178E06-A547-4F59-B3CB-7E0A6FB37422

P1476

Q36399686-1987ED52-1CF4-479B-A271-3EFD8C2E3892

P2093

Q36399686-0600925F-2DAD-4B4F-9B7E-B8797F5B8535

Q36399686-249AC14A-8768-40EF-8DD8-ACA6E57FE017

Q36399686-BC4D64EC-0ED7-4285-AADC-B7BE6D38126F

Q36399686-C505DE65-6D97-450C-952E-FFFD897DC43B

Q36399686-D3A9815D-3CDB-4073-90B0-C5A4D45FE877

Q36399686-DA6AE92B-A937-419D-85A7-7BB7D012DF87

P2860

Q36399686-00538254-C69B-4B7B-8BA5-B077A0E53E54

Q36399686-0537405C-6788-4B6A-A291-4449536B096C

Q36399686-0734A002-A30F-4C13-89BA-9AAEBB19873D

Q36399686-163F6B85-7C49-4562-8E53-2F2B2CB1A427

Q36399686-16641B1C-B2DD-4003-8CB1-827AA0FC5CDE

Q36399686-1FAF77A7-1E41-4CB5-A9BC-06CD52B403B6

Q36399686-23D7AB15-735A-4D0E-B311-956F14685F26

Q36399686-32341771-4A66-436D-A235-EFC7BA3A4EB2

Q36399686-350B617C-9E09-4A2E-B612-68BA1CBB7918

Q36399686-3987C8EE-13BF-4A92-9ABE-7245A8DD32A0

P304

Q36399686-87E316B8-DD4D-46D6-AA38-3B45AA584529

P31

Q36399686-11BEF896-DC52-4EBE-ACEE-E8F54D6E03D7

P356

Q36399686-C91715EA-B290-4546-8296-130CB9318947

P407

Q36399686-44F86CB2-6390-410A-8891-3AE15AB75725

P433

Q36399686-0CDAE821-0429-4CF6-8619-DDA167A1E59F

P478

Q36399686-C04A4EFE-5068-4C82-BD42-BA2524A59444

P577

Q36399686-398FBF1C-FA54-42CD-974F-96F3FA3238C7

P5875

Q36399686-3929C3BC-ECDA-4808-8A7E-E4AF4D8FD933

P698

Q36399686-EC4EFC01-D6DC-4A16-8A31-D6218EE6483F

P932

Q36399686-0F6EF890-310A-4E30-8190-D5616E928CC7

P356

P1433

Journal of Experimental Medicine

P1476

Concomitant tumor immunity to ...... evented by regulatory T cells.

@en

P2093

Alan N Houghton

http://www.w3.org/2001/XMLSchema#string

Gabrielle A Rizzuto

http://www.w3.org/2001/XMLSchema#string

José A Guevara-Patiño

http://www.w3.org/2001/XMLSchema#string

Manuel E Engelhorn

http://www.w3.org/2001/XMLSchema#string

Mary Jo Turk

http://www.w3.org/2001/XMLSchema#string

Shimon Sakaguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Control of regulatory T cell development by the transcription factor Foxp3

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

P304

771-782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20041130

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

200

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8332715

http://www.w3.org/2001/XMLSchema#string

P698

15381730

http://www.w3.org/2001/XMLSchema#string

P932

2211964

http://www.w3.org/2001/XMLSchema#string